Vision Statement VentriPoint creates diagnostic tools to monitor patients with heart disease -- the number one cause of death in developed countries. Using data from existing medical imaging devices, the VentriPoint Diagnostic System generates accurate heart measurements in a rapid and inexpensive manner that is not currently available. Company Overview VentriPoint commenced operations in January 2005 to develop and commercialize innovative and patented technologies developed by and licensed from the University of Washington. In September 2007, VentriPoint became the wholly owned subsidiary of VentriPoint Diagnostics Ltd. VentriPoint Diagnostics Ltd., is a public Canadian company with its common shares traded on the TSX Venture Exchange under the symbol "VPT", its only operations being those of VentriPoint, Inc. based in Seattle, Washington. The VentriPoint Diagnostic System and service creates critical information from existing medical imaging equipment using patented and proprietary methods, software and databases. As a web-based transactional fee service, the VentriPoint Diagnostic System automatically provides medical professionals with economical and accurate three-dimensional models and volume measurements of the heart ventricles, and most significant, the "difficult to measure" right ventricle. This critical information is provided in only minutes more than the time needed for a routine echocardiogram. VentriPoint anticipates seeding key sites with VentriPoint Diagnosttic System beta units in the summer of 2008. Commencement of trials for regulatory and publication purposes is scheduled to begin in the fall of 2008, with additional VentriPoint Diagnostic System beta units being deployed at this time. Initial commercial service is anticipated to commence in the first half of 2009. Company Fact Sheet Click here to view. |
